The possibilities of oral use of peptide drug and other new modalities
【紹介文献】
"Advances in oral peptide drug nanoparticles for diabetes mellitus treatment"
Yan Li et al, Bioactive Materials 15 (2022) 392–408.
"Charge-switchable zwitterionic polycarboxybetaine particle as an intestinal permeation enhancer for efficient oral insulin delivery"
Yan Li et al, Theranostics 2021, Vol. 11, Issue 9
【発表概要】
低分子以外のモダリティでは標的組織や投与方法に制約がかかりますが、画期的なDDS技術によって患者さんに新たな価値をお届けすることができます。今回のサイエンスカフェではペプチド医薬の経口ナノ粒子製剤化に着目した総説と論文を紹介し、経口化を目指す際の求められる性質や、様々なナノ粒子製剤の特徴を共有できればと思います。またペプチド医薬以外のモダリティへの応用などもディスカッションできれば幸いです。
【Summary】
Problems with modalities other than small molecules include limitations of target tissues and administration methods. Meanwhile, in recent years, innovative DDS technology has been developed to provide new value to patients. I introduce review articles and papers focusing on oral nanoparticle formulation of peptide drugs. I hope to share the properties of nanoparticles required for oral formulations, and characteristics of various nanoparticle formulations. I would also like to discuss about oral use in the case of other modalities.
(2022.9.1 Shonan iPark Science Cafe 125th)
